News & Events
Published On: 1/10/2019
TARGET PharmaSolutions to advance NASH Research through new collaboration
TARGET PharmaSolutions, Inc., a real-world data solutions company, is pleased to announce that Novartis has entered into a long-term strategic alliance for TARGET-NASH.
TARGET-NASH is a longitudinal observational study that evaluates adult and pediatric patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). TARGET-NASH will enroll up to 15,000 patients over the coming years. TARGET-NASH is led by an academic steering committee chaired by Drs. Arun Sanyal, MD (Virginia Commonwealth University); Ken Cusi, MD (University of Florida), and Brent Tetri (Saint Louis University).
Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions, stated “We are very excited to have Novartis join TARGET-NASH. TARGET-NASH has enrolled a large, diverse patient population and is generating valuable real-world data and insight on NASH, including the natural history of the disease and current treatment patterns. The TARGET real-world data solution which includes a biorepository and patient reported outcomes is a critical resource for our collaborators as they work to better understand and to combat this rapidly growing disease.”
TARGET PharmaSolutions provides insights and actions to improve clinical, medical, and commercial outcomes throughout the pharmaceutical development and commercialization process. The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes. This model enables TARGET’s stakeholders to answer critical strategic and planning questions. The TARGET model also provides its stakeholders access to a biorepository linked to validated clinical outcomes, including patient reported outcomes.
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
984.234.0268 ext 205
12/04/2023Overcoming Scalability Challenges in Real-World Data Processing for Transformative Patient Care
11/13/2023Real-World Evidence in Pharmaceutical Drug Development – Faster, Safer and More Relevant?
10/23/2023Leveraging Real-World Evidence with Analytics: 3 Essential Components to Capture a 360-Degree View of Your Patient Population
11/13/2023TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment Options
11/10/2023Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver Diseases